



25 November 2024

Market Announcement
National Stock Exchange (NSX)
1 Bligh Street
SYDNEY NSW, 2000

CEO Presentation To The Annual General Meeting

Welcome to the first Annual General Meeting of GODX Corporation (Aust) Ltd.

We are about delivering cutting-edge and proprietary technology in rapid diagnostics. We plan to leverage artificial intelligence and data analytics to empower individuals with personalised and effective healthcare solutions. Our intent is to promote health and wellness for all of humanity.

We intend to transform the field of diagnostics and wellness by building an ecosystem that leverages the power of molecular pathology, microbiome, health data, and artificial intelligence. We envision a future where every individual has access to personalise and accurate health information, enabling them to make informed decisions about their health and wellness. Our goal is to develop innovative solutions that not only diagnose but also prevent diseases, providing better health outcomes for all of humanity.

We thank Matthew Leonard and Justyn Stedwell who resigned as directors on 3rd October. We thank them for their contributions and wish them all the best for their future endeavors.

On 8th October, we welcomed William Bass and Cody Blackhurst as our incoming directors.

Danny Heng stepped down as CFO on 4th October. Dr. Ron Tan stepped down as Chief Scientific Officer on 31st October. We wish them all the best for their future endeavors.

The NSX IPO was completed on 16 July. We listed the company with a market capitalization of AUD61.941 million, at AUD0.38 per share. The majority of the funds raised at pre-IPO and IPO rounds would have been expended on IPO costs, operational expenses as well as audit costs.



In the prospectus we committed to number of actions. As an update I advise

1. There has been no further development or commercialisation of the RNA Mining/Mapping Platform and RNA Analytical Platform.
2. There has been no development of an AI-Enabled Platform relating to RNA Mining/Mapping/Analytical Platform accordingly.
3. There has been no further development or clinical validation of miRNA based biotechnologies for liquid biopsies for cancers.
4. There has been no further development of the intellectual property licensed to the Company to create novel inventions for the Company's use and exploitation.
5. Regarding the Pathomics Health investment we have completed payment of tranche 1 for 1.9% of Pathomics Health.

I will be updating all of these in three months' time.